Investigación Programas
Resistencia antimicrobiana

New antibacterial agents against 'Acinetobacter baumannii'

Search for new target proteins and use of antibacterial or inhibitory peptides against resistance mechanisms in 'Acinetobacter baumannii'

Foto: Janice Carr (Source: CDC library)
Duración
01/01/2018 - 31/12/2020
Coordinador
Jordi Vila
Financiadores
Mineco, Feder, ISCIII

At present a large proportion of available antibiotics are not suitable for the treatment of multiresistant pathogens. Sometimes the possibilities of choice are reduced to a single drug, as is the case of colistin for A. baumannii, in addition the new antibiotics are not active against this microorganism. In a recent document, the WHO positions A.baumannii at the top of the list of multiresistant microorganisms for which further research is required to find new antibacterial agents.

Objective

The main objective of this project is the design of new antibacterial agents against A. baumannii through several approaches:

1. Characterization of the role of active efflux systems (AESs) as well as other outer membrane proteins and double component systems in the virulence and resistance to antibiotics in A. baumannii, in order to search for potential target proteins;

2. Study of the capacity of blocking AESs by cyclic peptides;

3. We have a peptide with good antibacterial activity and its stability is being studied and its activity in vivo is also being investigated using a model of sepsis. The peptide will be optimized by synthesizing its enantiomer.

4. We have synthetized a peptide-oligonucleotide hybrid and in this project we will investigate its bactericidal capacity both in vitro and in vivo.

Total funding

111,300 €

Nuestro equipo

Principal Investigator

  • Jordi Vila
    Jordi Vila Research Professor, director de la Iniciativa de Resistencias Antimicrobianas y codirector del Programa de Infecciones Víricas y Bacterianas

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

Xpatial-TB

Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique

WHIP3TB

Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals

VINCI

Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique

INTE-AFRICA

Integrating and decentralizing diabetes and hypertension services in Africa

AVATAR

Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.

COVID-PREG

Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo

AMR DetecTool

A breakthrough device for the rapid detection of antimicrobial resistance

ANTICOV

Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19

HBV-COMSAVA

Hepatitis B Virus COMmunity Screening and Vaccination in Africans

Stool4TB

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

Hep C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.

CAPTB

Close the Gap, Increase Access, Provide Adequate Therapy

STREESCO

Strengthening Epidemiological Surveillance in Benin and Burkina Faso for an Effective Response to COVID-19

COVAIR-CAT

Air Pollution in Relation to COVID-19 Morbidity and Mortality: A Large Population-Based Cohort Study in Catalonia

TB-RECONNECT

Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status

SToolNIH

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring